Addendum
Olaparib (breast cancer, adjuvant) – Addendum to Commission A22-89
Report documents
-
Addendum
Olaparib (breast cancer, adjuvant) – Addendum to Commission A22-89
Dossier assessment
Indication:
Adult patients with germline BRCA-mutant, HER2-negative, high risk early breast cancer; after neoadjuvant or adjuvant chemotherapy; adjuvant treatment
Result of dossier assessment:
Unchanged after addendum: indication of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2023-02-16 A G-BA decision was published.
Project details
- Project no.
- A23-02
- Commission
- Commission awarded on 10.01.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed